Halozyme Therapeutics Inc.
Rating
Updated: Sep 7, 2026Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
Halozyme Therapeutics, Inc. is a biopharmaceutical company headquartered in San Diego, California, with operations spanning the United States, Switzerland, Ireland, Belgium, Japan, and other internati...
Latest News
4 days ago · prnewswire.com
Halozyme Therapeutics, Inc. Announces Pricing of Upsized Private Offering of $1.3 Billion of Convertible Senior Notes due 2033SAN DIEGO, Sept. 17, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company"), today announced the pricing of $1.3 billion aggregate principal amount of 1.50% convertible senior notes due 2033 (the "Convertible Notes").
5 days ago · prnewswire.com
Halozyme Therapeutics, Inc. Announces Proposed Offering of $1.05 Billion of Convertible Senior Notes due 2033SAN DIEGO, Sept. 16, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company"), today announced that it intends to offer, subject to market conditions and other factors, $1.05 billion aggregate principal amount of convertible senior notes due 2033 (the "Convertible Notes").
6 days ago · zacks.com
3 Reasons Why Growth Investors Shouldn't Overlook Halozyme Therapeutics (HALO)Halozyme Therapeutics (HALO) could produce exceptional returns because of its solid growth attributes.
6 days ago · seekingalpha.com
Halozyme Therapeutics, Inc. (HALO) Presents at H.C. Wainwright 28th Annual Global Investment Conference TranscriptHalozyme Therapeutics, Inc. (HALO) Presents at H.C. Wainwright 28th Annual Global Investment Conference Transcript
7 days ago · seekingalpha.com
Halozyme Therapeutics, Inc. (HALO) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptHalozyme Therapeutics, Inc. (HALO) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
7 days ago · zacks.com
4 Value Stocks to Buy as Oil Surge Fuels Fed Rate Hike FearsUnlock your portfolio value by investing in high earnings yield stocks like Ternium, Halozyme, POSCO and Talos Energy.
11 days ago · fxempire.com
Record Revenue Growth Boosts Halozyme SharesInstitutions have pushed Halozyme Therapeutics, Inc. (HALO) shares up 769% since March 2014.
13 days ago · seekingalpha.com
Halozyme Therapeutics, Inc. (HALO) Presents at Wells Fargo 21st Annual Healthcare Conference TranscriptHalozyme Therapeutics, Inc. (HALO) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
20 days ago · prnewswire.com
Halozyme to Participate at Upcoming Investor ConferencesSAN DIEGO, Sept. 2, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme") today announced that Dr. Helen Torley, President and Chief Executive Officer, and Darren Snellgrove, Chief Financial Officer, are scheduled to participate and host investor meetings at the following investor conferences.
22 days ago · seekingalpha.com
Halozyme: The Market May Be Underpricing The Second Growth WaveHalozyme Therapeutics is evolving into a diversified, high-margin royalty platform, reducing reliance on single assets like DARZALEX SC. HALO delivered 48% YoY revenue growth in 2Q26, with royalty revenue up 50% and EBITDA margins reaching 68%; full-year guidance was raised across all key metrics. Royalty streams are broadening across mature and new products, with sequential growth from recent launches and a robust pipeline targeting launches from 2029 onward.
Analyst Summary
Add to Watchlist
Select watchlists to add or remove HALO